z-logo
open-access-imgOpen Access
CpxR negatively regulates the production of xenocoumacin 1, a dihydroisocoumarin derivative produced by Xenorhabdus nematophila
Author(s) -
Zhang Shujing,
Fang Xiangling,
Tang Qian,
Ge Jing,
Wang Yonghong,
Zhang Xing
Publication year - 2019
Publication title -
microbiologyopen
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.881
H-Index - 36
ISSN - 2045-8827
DOI - 10.1002/mbo3.674
Subject(s) - mutant , biology , wild type , regulator , microbiology and biotechnology , gene , genetics
Xenocoumacin 1 (Xcn1), a major antimicrobial compound produced by Xenorhabdus nematophila , has great potential for use in agricultural productions. In this study, we evaluated the effects of CpxR, a global response regulator associated with the mutualism and pathogenesis of X .  nematophila , on the antimicrobial activity and Xcn1 production. The mutation of cpxR could promote the production of Xcn1 significantly with its level in ΔcpxR mutant being 3.07 times higher than that in the wild type. Additionally, the expression levels of xcnA‐L genes, which are responsible for the production of Xcn1, were increased in ΔcpxR mutant while the expression levels of xcn MN , which are required for the conversion of Xcn1 into Xcn2 was reduced. Noticeably, Xcn2 was also enhanced on account of the conversion of excessive Xcn1 in spite of low expression levels of xcnM and xcnN in ΔcpxR mutant. The transcriptional levels of ompR and lrp , encoding the global response regulators OmpR and Lrp which negatively and positively regulate the production of Xcn1 were concurrently decreased and increased, respectively. Correspondingly, ΔcpxR mutant also exhibited increased antimicrobial activities in vitro and in vivo. Together, these findings suggest that CpxR negatively regulates xcnA‐L genes expression while positively regulating xcn MN expression in X .  nematophila YL 001, which led to a high yield of Xcn1 in ΔcpxR mutant.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here